1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. SCILEX Pharmaceuticals Acquires Ancora Medical

M&A Deal Summary

SCILEX Pharmaceuticals Acquires Ancora Medical

On July 7, 2022, SCILEX Pharmaceuticals acquired medical products company Ancora Medical

Acquisition Highlights
  • This is SCILEX Pharmaceuticals’ 1st transaction in the Medical Products sector.
  • This is SCILEX Pharmaceuticals’ 2nd transaction in the United States.
  • This is SCILEX Pharmaceuticals’ 2nd transaction in California.

M&A Deal Summary
Date 2022-07-07
Target Ancora Medical
Sector Medical Products
Buyer(s) SCILEX Pharmaceuticals
Deal Type Add-on Acquisition

Target

Ancora Medical

Menlo Park, California, United States
Ancora Medical is a medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-operative periods associated with general and orthopedic surgery. Ancora Medical is based in Menlo Park, California.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

SCILEX Pharmaceuticals

Malvern, Pennsylvania, United States
Category Company
Founded 2011
Sector Life Science
DESCRIPTION

SCILEX Pharmaceuticals, Inc. develops and brings branded pharmaceutical products to market using technologies that are designed to maximize quality of life for all. SCILEX is working to deliver the next generation of products that are responsible by design. The Company's lead product candidate under development, ZTlido (lidocaine patch 1.8%), is a branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain.

DEAL STATS #
Overall 2 of 2
Sector: Medical Products M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: California M&A 2 of 2
Country: United States M&A 2 of 2
Year: 2022 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-01 Aardvark Therapeutics - ARD-301

San Diego, California, United States

Aardvark Therapeutics' ARD-301 proprietary formulation Delayed Burst Release Low Dose Naltrexone (DBR-LDN) used for the treatment of chronic pain, fibromyalgia, and chronic post-COVID syndrome. Aardvark Therapeutics' ARD-301 is based in San Diego, California.

Buy -
Mergr

Solution for

Product

Company

Legal